1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. NEUROPATHY PAIN MARKET BY DRUG CLASS
5.1. Introduction
5.2. Tricyclic Anti-Depressant
5.2.1. Market Trends and Opportunities
5.2.2. Growth Prospects
5.3. Anticonvulsant
5.3.1. Market Trends and Opportunities
5.3.2. Growth Prospects
5.4. Local Anesthesia
5.4.1. Market Trends and Opportunities
5.4.2. Growth Prospects
5.5. Opioids
5.5.1. Market Trends and Opportunities
5.5.2. Growth Prospects
5.6. Steroids
5.6.1. Market Trends and Opportunities
5.6.2. Growth Prospects
5.7. Others
5.7.1. Market Trends and Opportunities
5.7.2. Growth Prospects
6. NEUROPATHY PAIN MARKET BY INDICATION
6.1. Introduction
6.2. Diabetic neuropathy
6.2.1. Market Trends and Opportunities
6.2.2. Growth Prospects
6.3. Chemotherapy-induced Peripheral neuropathy
6.3.1. Market Trends and Opportunities
6.3.2. Growth Prospects
6.4. Others
6.4.1. Market Trends and Opportunities
6.4.2. Growth Prospects
7. NEUROPATHY PAIN MARKET BY DISTRIBUTION CHANNEL
7.1. Introduction
7.2. Retail Pharmacies
7.2.1. Market Trends and Opportunities
7.2.2. Growth Prospects
7.3. Drug Store
7.3.1. Market Trends and Opportunities
7.3.2. Growth Prospects
7.4. Online Pharmacies
7.4.1. Market Trends and Opportunities
7.4.2. Growth Prospects
8. NEUROPATHY PAIN MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Drug Class
8.2.2. By Indication
8.2.3. By Distribution Channel
8.2.4. By Country
8.2.4.1. United States
8.2.4.1.1. Market Trends and Opportunities
8.2.4.1.2. Growth Prospects
8.2.4.2. Canada
8.2.4.2.1. Market Trends and Opportunities
8.2.4.2.2. Growth Prospects
8.2.4.3. Mexico
8.2.4.3.1. Market Trends and Opportunities
8.2.4.3.2. Growth Prospects
8.3. South America
8.3.1. By Drug Class
8.3.2. By Indication
8.3.3. By Distribution Channel
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.1.1. Market Trends and Opportunities
8.3.4.1.2. Growth Prospects
8.3.4.2. Argentina
8.3.4.2.1. Market Trends and Opportunities
8.3.4.2.2. Growth Prospects
8.3.4.3. Others
8.3.4.3.1. Market Trends and Opportunities
8.3.4.3.2. Growth Prospects
8.4. Europe
8.4.1. By Drug Class
8.4.2. By Indication
8.4.3. By Distribution Channel
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.1.1. Market Trends and Opportunities
8.4.4.1.2. Growth Prospects
8.4.4.2. Germany
8.4.4.2.1. Market Trends and Opportunities
8.4.4.2.2. Growth Prospects
8.4.4.3. France
8.4.4.3.1. Market Trends and Opportunities
8.4.4.3.2. Growth Prospects
8.4.4.4. Italy
8.4.4.4.1. Market Trends and Opportunities
8.4.4.4.2. Growth Prospects
8.4.4.5. Spain
8.4.4.5.1. Market Trends and Opportunities
8.4.4.5.2. Growth Prospects
8.4.4.6. Others
8.4.4.6.1. Market Trends and Opportunities
8.4.4.6.2. Growth Prospects
8.5. Middle East and Africa
8.5.1. By Drug Class
8.5.2. By Indication
8.5.3. By Distribution Channel
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.1.1. Market Trends and Opportunities
8.5.4.1.2. Growth Prospects
8.5.4.2. UAE
8.5.4.2.1. Market Trends and Opportunities
8.5.4.2.2. Growth Prospects
8.5.4.3. Others
8.5.4.3.1. Market Trends and Opportunities
8.5.4.3.2. Growth Prospects
8.6. Asia Pacific
8.6.1. By Drug Class
8.6.2. By Indication
8.6.3. By Distribution Channel
8.6.4. By Country
8.6.4.1. Japan
8.6.4.1.1. Market Trends and Opportunities
8.6.4.1.2. Growth Prospects
8.6.4.2. China
8.6.4.2.1. Market Trends and Opportunities
8.6.4.2.2. Growth Prospects
8.6.4.3. India
8.6.4.3.1. Market Trends and Opportunities
8.6.4.3.2. Growth Prospects
8.6.4.4. South Korea
8.6.4.4.1. Market Trends and Opportunities
8.6.4.4.2. Growth Prospects
8.6.4.5. Taiwan
8.6.4.5.1. Market Trends and Opportunities
8.6.4.5.2. Growth Prospects
8.6.4.6. Thailand
8.6.4.6.1. Market Trends and Opportunities
8.6.4.6.2. Growth Prospects
8.6.4.7. Indonesia
8.6.4.7.1. Market Trends and Opportunities
8.6.4.7.2. Growth Prospects
8.6.4.8. Others
8.6.4.8.1. Market Trends and Opportunities
8.6.4.8.2. Growth Prospects
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Pfizer, Inc.
10.2. Sanofi S.A.
10.3. Eily Lily and Company
10.4. GlaxoSmithKline PLC
10.5. Biogen Idec.
10.6. Bristol-Myers Squibb
10.7. Baxter Healthcare Corporation